Eisai's High Dose Aricept Beats Expectations, But Lack Of Solutions Plague Mid-term Forecast
This article was originally published in PharmAsia News
TOKYO - A higher-dose Aricept anti-Alzheimer treatment U.S. FDA approved this summer is set to be a core revenue contributor for Eisai through its business year ending next March and on, and if its endotoxin antagonist eritoran for severe sepsis is approved, the growth momentum could continue through 2012, according to Eisai and analysts
You may also be interested in...
TOKYO - Eisai will launch a "substantial marketing campaign" behind the recent U.S. approval of high-dose Aricept (donepezil) as the company races to move moderate to severe Alzheimer's disease patients that could benefit from higher doses of the drug from the 10 mg dosage to the newly approved 23 mg dosage ahead of Aricept 10 mg's November 2010 patent loss
TOKYO - Eisai March 31 said it had applied for manufacturing and marketing approval with Japan's Ministry of Health, Labor and Welfare; U.S. FDA and the European Medicines Agency for eribulin for the treatment of locally advanced and metastatic breast cancer
The diet pill was not approved or recommended for use in about 90 percent of patients in the trial that triggers the warning, Abbott says.